164 related articles for article (PubMed ID: 33649516)
1. The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.
Shiota M; Akamatsu S; Narita S; Sumiyoshi T; Fujiwara M; Uchiumi T; Ogawa O; Habuchi T; Eto M
Pharmacogenomics J; 2021 Aug; 21(4):440-445. PubMed ID: 33649516
[TBL] [Abstract][Full Text] [Related]
2. Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.
Shiota M; Narita S; Akamatsu S; Fujimoto N; Sumiyoshi T; Fujiwara M; Uchiumi T; Habuchi T; Ogawa O; Eto M
JAMA Netw Open; 2019 Feb; 2(2):e190115. PubMed ID: 30794306
[TBL] [Abstract][Full Text] [Related]
3. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
Lu C; Terbuch A; Dolling D; Yu J; Wang H; Chen Y; Fountain J; Bertan C; Sharp A; Carreira S; Isaacs WB; Antonarakis ES; De Bono JS; Luo J
Ann Oncol; 2020 Sep; 31(9):1178-1185. PubMed ID: 32387417
[TBL] [Abstract][Full Text] [Related]
4. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
[TBL] [Abstract][Full Text] [Related]
5. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
Almassi N; Reichard C; Li J; Russell C; Perry J; Ryan CJ; Friedlander T; Sharifi N
JAMA Oncol; 2018 Apr; 4(4):554-557. PubMed ID: 29049452
[TBL] [Abstract][Full Text] [Related]
6. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
Alyamani M; Emamekhoo H; Park S; Taylor J; Almassi N; Upadhyay S; Tyler A; Berk MP; Hu B; Hwang TH; Figg WD; Peer CJ; Chien C; Koshkin VS; Mendiratta P; Grivas P; Rini B; Garcia J; Auchus RJ; Sharifi N
J Clin Invest; 2018 Aug; 128(8):3333-3340. PubMed ID: 29939161
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Trial of Abiraterone With Dutasteride for Second-Generation Antiandrogen- and Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer.
Shiota M; Inoue R; Tashiro K; Kobayashi K; Horiyama S; Kanji H; Eto M; Egawa S; Haginaka J; Matsuyama H
J Clin Pharmacol; 2023 Apr; 63(4):445-454. PubMed ID: 36484758
[TBL] [Abstract][Full Text] [Related]
8. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Hearn JWD; Sweeney CJ; Almassi N; Reichard CA; Reddy CA; Li H; Hobbs B; Jarrard DF; Chen YH; Dreicer R; Garcia JA; Carducci MA; DiPaola RS; Sharifi N
JAMA Oncol; 2020 Apr; 6(4):e196496. PubMed ID: 32053149
[TBL] [Abstract][Full Text] [Related]
9. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.
Hettel D; Sharifi N
Nat Rev Urol; 2018 Mar; 15(3):191-196. PubMed ID: 29231195
[TBL] [Abstract][Full Text] [Related]
10. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
[TBL] [Abstract][Full Text] [Related]
11. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E
Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722
[TBL] [Abstract][Full Text] [Related]
12. Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.
Wang Z; Deng T; Long X; Lin X; Wu S; Wang H; Ge R; Zhang Z; Wu CL; Taplin ME; Olumi AF
PLoS One; 2020; 15(3):e0229754. PubMed ID: 32134978
[TBL] [Abstract][Full Text] [Related]
13. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.
Hearn JWD; AbuAli G; Reichard CA; Reddy CA; Magi-Galluzzi C; Chang KH; Carlson R; Rangel L; Reagan K; Davis BJ; Karnes RJ; Kohli M; Tindall D; Klein EA; Sharifi N
Lancet Oncol; 2016 Oct; 17(10):1435-1444. PubMed ID: 27575027
[TBL] [Abstract][Full Text] [Related]
14. Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate.
Takahashi Y; Narita S; Shiota M; Miura M; Kagaya H; Kashima S; Yamamoto R; Nara T; Huang M; Numakura K; Saito M; Eto M; Habuchi T
Eur J Clin Pharmacol; 2023 Jan; 79(1):89-98. PubMed ID: 36378297
[TBL] [Abstract][Full Text] [Related]
15. Germline HSD3B1 Genetics and Prostate Cancer Outcomes.
Thomas L; Sharifi N
Urology; 2020 Nov; 145():13-21. PubMed ID: 32866512
[TBL] [Abstract][Full Text] [Related]
16. Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.
Wu G; Huang S; Nastiuk KL; Li J; Gu J; Wu M; Zhang Q; Lin H; Wu D
Prostate; 2015 May; 75(7):777-782. PubMed ID: 25731771
[TBL] [Abstract][Full Text] [Related]
17. Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.
Hearn JWD; Xie W; Nakabayashi M; Almassi N; Reichard CA; Pomerantz M; Kantoff PW; Sharifi N
JAMA Oncol; 2018 Apr; 4(4):558-562. PubMed ID: 29049492
[TBL] [Abstract][Full Text] [Related]
18. HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond.
Sabharwal N; Sharifi N
Endocrinology; 2019 Sep; 160(9):2180-2188. PubMed ID: 31271415
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer.
Stangl-Kremser J; Lemberger U; Hassler MR; Bruchbacher A; Ilijazi D; Garstka N; Kramer G; Haitel A; Abufaraj M; Shariat SF
Clin Genitourin Cancer; 2019 Oct; 17(5):389-394. PubMed ID: 31331867
[TBL] [Abstract][Full Text] [Related]
20. Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors.
Shiota M; Akamatsu S; Sekine Y; Kimura H; Narita S; Fujimoto N; Terada N; Blas L; Habuchi T; Kamoto T; Momozawa Y; Eto M
Cancer Sci; 2023 Apr; 114(4):1625-1634. PubMed ID: 36602227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
